Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin
- PMID: 11157679
- DOI: 10.1161/01.res.88.2.245
Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin
Abstract
Recent studies have shown that antiphospholipid (aPL) enhances expression of intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin on endothelial cells (ECs) and that these effects are correlated with increased adhesion of leukocytes to endothelium in cremaster muscle in vivo and with thrombosis in a mouse model. Activation of ECs by aPL may create a hypercoagulable state that precedes and contributes to thrombosis in patients with aPL syndrome (APS). This study proposed to examine whether this in vivo activation of ECs and enhanced thrombosis by aPL are mediated by ICAM-1, P-selectin, or VCAM-1. The dynamics of thrombus formation and the number of adhering leukocytes were studied in ICAM-1-deficient (ICAM-1(-/-)) mice or ICAM-1-/P-selectin-deficient (ICAM-1(-/-)/P-selectin(-/-)) mice treated with affinity-purified aPL antibodies (ap IgG-APS) or with control IgG and compared with wild-type mice treated in a similar fashion. In another set of experiments, the adhesion of leukocytes to cremaster muscle and the dynamics of thrombus formation were studied in CD1 mice treated with aPL or control IgG before and 30 minutes after intravenous infusion with 100 microg monoclonal antibody anti-VCAM-1. The results indicate that the enhanced adhesion of leukocytes to endothelium in wild-type mice was significantly reduced in ICAM-1(-/-) and completely abrogated in ICAM-1(-/-)/P-selectin(-/-) mice treated with ap IgG-APS compared with wild-type mice treated with ap IgG-APS (6.9+/-2.3, 0.4+/-0.4 versus 35+/-12, respectively). More importantly, this correlated with a significant reduction in thrombus size compared with wild-type mice treated with ap IgG-APS (895+/-259 microm(2), 859+/-243 microm(2) versus 3816+/-672 microm(2), respectively). Infusion of the mice with anti-VCAM-1 antibodies significantly reversed the enhanced adhesion of leukocytes (14.9+/-3 to 11.3+/-2.1) and thrombus size 3830+/-1008 microm(2) versus 876+/-548 microm(2)) in mice treated with ap IgG-APS. The data indicate that ICAM-1, P-selectin, and VCAM-1 expression are important in thrombotic complications by aPL antibodies and may provide novel targets for therapy in patients with APS.
Similar articles
-
Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.Lupus. 2003;12(7):539-45. doi: 10.1191/961203303lu398oa. Lupus. 2003. PMID: 12892395 Review.
-
E-Selectin mediates pathogenic effects of antiphospholipid antibodies.J Thromb Haemost. 2003 Apr;1(4):843-8. doi: 10.1046/j.1538-7836.2003.00119.x. J Thromb Haemost. 2003. PMID: 12871424
-
Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.Circulation. 1999 Apr 20;99(15):1997-2002. doi: 10.1161/01.cir.99.15.1997. Circulation. 1999. PMID: 10209004
-
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.Arthritis Rheum. 2003 Nov;48(11):3272-9. doi: 10.1002/art.11449. Arthritis Rheum. 2003. PMID: 14613293
-
Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies.Thromb Res. 2004;114(5-6):467-76. doi: 10.1016/j.thromres.2004.06.031. Thromb Res. 2004. PMID: 15507280 Review.
Cited by
-
Association of XIST/miRNA155/Gab2/TAK1 cascade with the pathogenesis of anti-phospholipid syndrome and its effect on cell adhesion molecules and inflammatory mediators.Sci Rep. 2023 Nov 1;13(1):18790. doi: 10.1038/s41598-023-45214-z. Sci Rep. 2023. PMID: 37914735 Free PMC article.
-
Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.Clin Rheumatol. 2017 Dec;36(12):2859-2867. doi: 10.1007/s10067-017-3823-2. Epub 2017 Sep 13. Clin Rheumatol. 2017. PMID: 28905254
-
Understanding the Pathophysiology of Thrombotic APS through Animal Models.Int J Mol Sci. 2021 Mar 4;22(5):2588. doi: 10.3390/ijms22052588. Int J Mol Sci. 2021. PMID: 33806694 Free PMC article. Review.
-
Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.Am J Pathol. 2003 Sep;163(3):1193-200. doi: 10.1016/S0002-9440(10)63479-7. Am J Pathol. 2003. PMID: 12937161 Free PMC article.
-
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.J Clin Invest. 2011 Jan;121(1):120-31. doi: 10.1172/JCI39828. Epub 2010 Dec 1. J Clin Invest. 2011. PMID: 21123944 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous